SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : T/FIF, a New Plateau

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: scaram(o)uche who wrote (942)2/6/2002 4:54:12 PM
From: scaram(o)uche  Read Replies (1) of 2243
 
Wednesday February 6, 4:48 pm Eastern Time
TEXT-S&P may cut Elan Corp Plc ratings
(UPDATE: Press release provided by Standard & Poor's)

NEW YORK, Feb 6 - Standard & Poor's today placed all of its ratings on Elan Corp. PLC (NYSE:ELN - news) on CreditWatch with negative implications (see list below). The actions were taken following Elan's announcement of higher-than-expected R&D and marketing expenditures, and the possibility of

slower-than-expected product sales growth. The company also announced that it plans to pursue further product acquisitions.

Elan continues to maintain a significant level of financial flexibility. Including amounts held in the off-balance sheet (for U.S. GAAP purposes), Qualified Special Purpose Entities (EPIL II and III), Elan has cash and investments of over $3.8 billion, which exceeds the company's $3 billion in debt.

Elan may utilize a significant portion of its financial flexibility, given its announced plans to raise R&D expenditures, expand its U.S. and European marketing infrastructures, and pursue further acquisitions. Elan has historically used a significant amount of equity financing for its acquisitions, but, with the recent steep decline in its equity share price, Elan may have to use a higher percentage of cash financing for its future transactions. Elan also said that product sales growth may slow, due to delays in obtaining FDA product approvals.

Standard & Poor's intends to assess Elan's projected financial flexibility and its levels of sustainable funds from operations, especially given recent questions regarding the company's accounting of R&D revenues, before resolving the CreditWatch.

Ratings Placed on Creditwatch Negative

Elan Corp. PLC Rating
Corporate credit rating BBB
Senior unsecured debt BBB
Subordinated debt BBB-

Athena Neurosciences Finance LLC
*Senior unsecured debt BBB
Dura Pharmaceuticals Inc.
Subordinated debt BBB-
Elan Finance Corp. Ltd.
*Subordinated debt BBB-
Elan Pharmaceutical Investments II Ltd.
*Subordinated debt BBB-
Elan Pharmaceutical Investments III Ltd.
*Subordinated debt BBB-
*Guarantor: Elan Corp. PLC
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext